Janet Pope
Tweet
Which pt has more MIs post elective surgery? #ACR21 @RheumNow abst#0128
All News
Aurelie Najm
Tweet
Finally a way to improve Fatigue in RMDs? PLUS it is non pharmaceutical and remote⚡️! Cognitive Behavioural approaches and Personalised Exercise Interventions:
⬇️ Fatigue Severity and Impact
⬆️ Sleep at 1yr in a multiarm RCT.
#OP0462 @RheumNow #ACR2021 https://t.co/5buGCYb5Ut https://t.co/4Wz2VmcL3x
TheDaoIndex
Tweet
Winning Image Competition: Rheum Dz in Patients of Color: Dermatomyositis #ACR21 @rheumnow https://t.co/OFRDDgQqas
TheDaoIndex
Tweet
Erosive polyarticular chronic tophaceous gout
Regional Winner of East Asia and Pacific
Image Competition: Rheum Dz in Patients of Color
#ACR21 @rheumnow https://t.co/1wrNAhjsw6
Pedro Castillo
Tweet
SLE patients with +aPL was associated with:
➡️Nephritis
➡️Discoid rash
➡️Serositis
➡️Neurologic disorder
Consider aPL and LAC status in patients w/these manifestations and whether anticoagulation/antiplatelets may be needed
#ACR21 Abst#0077 @RheumNow
TheDaoIndex
Tweet
Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation
Regional Winner of Europe & Central Asia
Image Competition: Rheum Dz in Patients of Color
#ACR21 @rheumnow https://t.co/vxayxgINa8
TheDaoIndex
Tweet
Lichenoid cutaneous lupus erythematosus mimicking acanthosis nigricans
Regional Winner of Latin America and Caribbean
Image Competition: Rheum Dz in Patients of Color
#ACR21 @rheumnow https://t.co/4oAXIClwsm
Eric Dein
Tweet
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19.
▶️150 mg RZB vs Placebo
⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI
⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn
⭐️No safety signal
https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd
Janet Pope
Tweet
#SLE pts have equal rates of post op CV events compared to TypeII DM pts and ⬆️ compared to matched controls. Esp driven by comorbidities. Should we add ASA post op in SLE pts with CV risks? #ACR21 #abst0128 @RheumNow https://t.co/COdbDxFgBQ
Dr. Rachel Tate
Tweet
Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i
TheDaoIndex
Tweet
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉phase 3 DBRPCT 24 weeks
👉150 mg week 0,4, 16 weeks
👉improved ACR20,ACR50,ACR70
👉improved PASI90
👉improved HAQ-DI
👉no increased safety signals
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
Akhil Sood MD
Tweet
Abs 0463 #ACR21 @RheumNow
Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database
- Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
Eric Dein
Tweet
#ACR21 Abst#0454
Lupus nephritis mortality from 1999-2019
⭐️-27% age-standardized mortality rate in LN death, though increased trend in last 5 yrs!
▶️ Afr-American 38% of deaths, though 12% of population (RR ~4.5), ⬆️mortality with urbanization
https://t.co/fjeGXtItvD @RheumNow https://t.co/cE3t6lq8zi
sheila
Tweet
Promising results of Risankizumab for #psoriaticarthritis
🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo
🔸Well tolerated and showed no safety signals
@RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
swethaann23
Tweet
#ACR21 @RheumNow
Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2017
⭐️Higher spinal disease: Male gender; longer disease duration; smoking
⭐️🔼Disease progression 🔼CRP levels
⭐️🔽Disease progression with time-varying TNFI use https://t.co/XsKp28HOxz
Aurelie Najm
Tweet
Pre clinical RA: don't miss the feet 🦶🏼! Among 577 patients
with clinically suspect arthralgia undergoing MRI:
-23% intermetatarsal bursitis > ACPA + 56% vs. 19%
-higher risk or RA HR 3.3.
Would we find the same results w/ US?
#OP0468 @RheumNow #ACR2021 https://t.co/VkzUu93qGq https://t.co/GGw7UgdPVR
sheila
Tweet
Accdg to this study by Dr. B VanDijk et al, intermetatarsal bursitis (IMB) was seen in 23% of clin suspect arthralgia(CSA) pts; predicted clinical arthritis in ACPA+; ⬆ frequent w/ synovitis & tenosynovitis
Addtl tool for early RA dx?
@RheumNow #ACR21 abs0468 #ACRBest https://t.co/bcUuy8bHLJ
Robert B Chao, MD
Tweet
AxSpA pts share a gut microbiome signature with Crohn's disease and anterior uveitis pts
⬇️Blautia
⬆️Veillonella and Lactobacillus
⭐️SpA pts uniquely enriched in Collinsella
Abs#0062 #ACR21 @RheumNow #ACRBest
https://t.co/sdlHxNbhr8 https://t.co/r8eG9c9vwa
Dr. Rachel Tate
Tweet
Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disability vs SES. Dz severity strong predictor of adverse work outcome despite advanced therapeutic strategies in axSpA. Abs 0381 #ACR21 #RheumNow @RheumNow https://t.co/Lc3yUgXvw6
Eric Dein
Tweet
#ACR21 Abst#0455 ARIAA Study: Abatacept for subclinical arthritis
⭐️ ACPA + arthralgia + MRI inflammation 🔥
⭐️ ⬇️ MRI inflam (primary) and ⬇️ progression to arthritis (secondary)
▶️ Many patients likely early RA, would still rec starting MTX 1st
https://t.co/4aREvqlpUI @Rheumnow https://t.co/vqRgsd75Il
